EA200301042A1 - Азолопиримидины - Google Patents
АзолопиримидиныInfo
- Publication number
- EA200301042A1 EA200301042A1 EA200301042A EA200301042A EA200301042A1 EA 200301042 A1 EA200301042 A1 EA 200301042A1 EA 200301042 A EA200301042 A EA 200301042A EA 200301042 A EA200301042 A EA 200301042A EA 200301042 A1 EA200301042 A1 EA 200301042A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- azolopirimidines
- psychiatric
- anxiety
- immunological
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Настоящее изобретение относится к антагонистам формул (1) или (2)где А представляет CR, и их использованию для лечения тревожного состояния, депрессии и других психиатрических, неврологических заболеваний, а также для лечения иммунологических, сердечно-сосудистых или связанных с сердцем заболеваний и повышенной чувствительности толстой кишки, связанной с психологическим нарушением и стрессом.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68604796A | 1996-07-24 | 1996-07-24 | |
US2329096P | 1996-07-24 | 1996-07-24 | |
US08/899,242 US6124289A (en) | 1996-07-24 | 1997-07-23 | Azolo triazines and pyrimidines |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200301042A1 true EA200301042A1 (ru) | 2004-02-26 |
EA006626B1 EA006626B1 (ru) | 2006-02-24 |
Family
ID=26696934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200301042A EA006626B1 (ru) | 1996-07-24 | 1997-07-23 | Азолопиримидины, фармацевтическая композиция и способ лечения |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP0915880B1 (ru) |
KR (1) | KR100548853B1 (ru) |
AR (1) | AR007994A1 (ru) |
AT (1) | ATE375344T1 (ru) |
AU (1) | AU747708B2 (ru) |
CZ (1) | CZ2005613A3 (ru) |
DE (1) | DE69738197T2 (ru) |
DK (1) | DK0915880T3 (ru) |
EA (1) | EA006626B1 (ru) |
ES (1) | ES2294800T3 (ru) |
HK (1) | HK1052693A1 (ru) |
HU (2) | HU229024B1 (ru) |
LV (1) | LV12292B (ru) |
PT (1) | PT915880E (ru) |
RO (1) | RO121272B1 (ru) |
TW (2) | TWI238164B (ru) |
WO (1) | WO1998003510A1 (ru) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
EP0970082A2 (en) * | 1997-02-18 | 2000-01-12 | Neurocrine Biosciences, Inc. | Biazacyclic crf antagonists |
NZ505079A (en) * | 1998-01-28 | 2003-08-29 | Du Pont Pharm Co | Pyrazolotriazines and pyrazolopyrimidines useful as corticotropin releasing factor antagonists |
US6613777B1 (en) | 1998-03-06 | 2003-09-02 | Chen Chen | CRF antagonistic pyrazolo[4,3-b]pyridines |
US6509338B1 (en) * | 1998-06-22 | 2003-01-21 | Bristol-Myers Squibb Company | Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists |
US6348466B1 (en) | 1998-11-12 | 2002-02-19 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
ES2180338T3 (es) | 1998-11-12 | 2003-02-01 | Neurocrine Biosciences Inc | Antagonistas del receptor de crf y metodos relacionados. |
WO2000059908A2 (en) * | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
AU4331500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolotriazines as crf antagonists |
US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
US6372743B1 (en) | 1999-09-30 | 2002-04-16 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines |
ES2277855T3 (es) * | 1999-09-30 | 2007-08-01 | Neurogen Corporation | Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas. |
US6506762B1 (en) | 1999-09-30 | 2003-01-14 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
AU2001232271A1 (en) * | 2000-02-14 | 2001-08-20 | Japan Tobacco Inc. | Preventives/remedies for postoperative stress |
WO2002006286A2 (en) * | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
CN1446316A (zh) * | 2000-08-02 | 2003-10-01 | 玛洛普有限公司 | 基于下丘脑-垂体-肾上腺轴异常的非溃疡性消化不良的诊断和处置 |
RU2292347C2 (ru) | 2001-03-13 | 2007-01-27 | Бристоль-Мейерз Сквибб Фарма Компани | 4-(2-БУТИЛАМИНО)-2,7-ДИМЕТИЛ-8-(2-МЕТИЛ-6-МЕТОКСИПИРИД-3-ИЛ)ПИРАЗОЛО-[1,5-а]-1,3,5-ТРИАЗИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЕГО СОДЕРЖАЩАЯ, И ЕГО ПРИМЕНЕНИЕ |
CA2446980A1 (en) | 2001-05-14 | 2002-11-21 | Argyrios G. Arvanitis | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
WO2003005969A2 (en) | 2001-07-12 | 2003-01-23 | Bristol-Myers Squibb Pharma Company | Tetrahydropurinones as corticotropin releasing factor |
US7276526B2 (en) | 2001-07-13 | 2007-10-02 | Bristol-Myers Squibb Pharma Company | Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands |
US20030119831A1 (en) | 2001-11-20 | 2003-06-26 | Hartz Richard A. | 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands |
DE60301339T2 (de) | 2002-03-07 | 2006-03-09 | Smithkline Beecham Corp. | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen |
ES2298513T3 (es) * | 2002-04-26 | 2008-05-16 | Eli Lilly And Company | Derivados de tiazol como antagonistas del receptor de taquicinina. |
FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
FR2850653A1 (fr) * | 2003-02-04 | 2004-08-06 | Univ Pasteur | Derives de pyrazolotriazine, procede de preparation et utilisations |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7112585B2 (en) | 2003-04-18 | 2006-09-26 | Bristol-Myers Squibb Company | Pyrimidine derivatives as corticotropin releasing factor inhibitors |
US7030145B2 (en) | 2003-04-18 | 2006-04-18 | Bristol-Myers Squibb Company | Pyridinyl derivatives for the treatment of depression |
US7208596B2 (en) | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
US7153961B2 (en) | 2003-11-25 | 2006-12-26 | Bristol-Myers Squibb Pharma Co. | Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist |
WO2005063755A1 (en) | 2003-12-22 | 2005-07-14 | Sb Pharmco Puerto Rico Inc | Crf receptor antagonists and methods relating thereto |
GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
US20100216798A1 (en) * | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
CN101516886B (zh) | 2006-09-20 | 2012-02-29 | 伊莱利利公司 | 噻吩吡唑并嘧啶化合物 |
PL2094709T3 (pl) * | 2006-09-20 | 2011-02-28 | Lilly Co Eli | Tiazolopirazolopirymidyny jako antagoniści receptora crf1 |
JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
AR064491A1 (es) | 2006-12-22 | 2009-04-08 | Astex Therapeutics Ltd | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. |
EP2522351B1 (en) * | 2007-06-13 | 2017-09-06 | Research Development Foundation | Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
WO2010118207A1 (en) | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
EP2264035A1 (en) * | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | Glycine B antagonists |
EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
PL2760453T3 (pl) | 2011-09-30 | 2016-11-30 | Makrocykliczne Inhibitory kinazy LRRK2 | |
GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
CN105164124B (zh) | 2012-11-19 | 2017-03-15 | 诺华股份有限公司 | 用于治疗寄生虫疾病的化合物和组合物 |
CN107501275B (zh) | 2012-12-07 | 2019-11-22 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物 |
WO2014144801A1 (en) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Methods and compositions for improving cognitive function |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
RU2720408C2 (ru) | 2013-12-06 | 2020-04-29 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения ингибиторов atr киназы (варианты) |
AU2015271030B2 (en) | 2014-06-05 | 2019-05-16 | Vertex Pharmaceuticals Incorporated | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof |
ES2733847T3 (es) | 2014-06-17 | 2019-12-03 | Vertex Pharma | Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR |
WO2016042089A1 (en) | 2014-09-17 | 2016-03-24 | Oncodesign S.A. | Macrocyclic lrrk2 kinase inhibitors |
AU2015342021B2 (en) | 2014-11-03 | 2020-02-27 | Bayer Pharma Aktiengesellschaft | Piperidinylpyrazolopyrimidinones and their use |
EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
US20210032253A1 (en) * | 2018-02-06 | 2021-02-04 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof |
MX2021004769A (es) | 2018-10-30 | 2021-08-24 | Kronos Bio Inc | Compuestos, composiciones, y metodos para modular la actividad cdk9. |
WO2022036123A1 (en) | 2020-08-12 | 2022-02-17 | Spruce Biosciences, Inc. | Methods and compositions for treating polycystic ovary syndrome |
US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE786611A (fr) * | 1971-08-16 | 1973-01-22 | Int Chem & Nuclear Corp | Nouveaux inhibiteurs de xanthine-oxydase et leur procede de preparatio |
US3910907A (en) * | 1973-07-09 | 1975-10-07 | Icn Pharmaceuticals | Pyrazolo(1,5-a)-1,3,5-triazines |
US3995039A (en) * | 1975-05-27 | 1976-11-30 | Merck & Co., Inc. | Pyrazolo [1,5-a] [1,3,5] triazines |
JPS6157587A (ja) * | 1984-08-29 | 1986-03-24 | Shionogi & Co Ltd | 縮合複素環誘導体および抗潰瘍剤 |
US4824834A (en) * | 1986-10-31 | 1989-04-25 | Otsuka Pharmaceutical Company, Limited | Pyrazolotriazine compounds |
DE3722072A1 (de) * | 1987-07-01 | 1989-01-12 | Schering Ag | 6,7-dihydro-pyrazolo(1,5-a)(1,3,5) triazin-2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider und pflanzenwuchsregulierender wirkung |
JP2585462B2 (ja) * | 1989-10-25 | 1997-02-26 | 株式会社大塚製薬工場 | ピラゾロ[1,5―a]ピリミジン誘導体 |
US5420128A (en) * | 1990-10-09 | 1995-05-30 | Otsuka Pharmaceutical Co., Ltd. | Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor |
US5484760A (en) * | 1990-12-31 | 1996-01-16 | Monsanto Company | Herbicide antidotes as safeners for reducing phytotoxicity resulting from synergistic interaction between herbicides and other pesticides |
DE69130683T2 (de) * | 1991-04-22 | 1999-05-06 | Otsuka Pharma Co Ltd | PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL |
US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
US6765008B1 (en) * | 1992-12-17 | 2004-07-20 | Pfizer Inc | Pyrrolopyrimidines as CRF antagonists |
KR100315837B1 (ko) * | 1994-06-21 | 2002-02-28 | 고리 히데아끼 | 피라졸로[1,5-a]피리미딘유도체 |
KR100256707B1 (ko) * | 1995-05-12 | 2000-05-15 | 해피 페너 | 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드 |
EP0880523B1 (en) * | 1996-02-07 | 2006-08-16 | Neurocrine Biosciences, Inc. | Pyrazolopyrimidines as crf receptor antagonists |
-
1997
- 1997-07-23 AT AT97936222T patent/ATE375344T1/de active
- 1997-07-23 DK DK97936222T patent/DK0915880T3/da active
- 1997-07-23 EP EP97936222A patent/EP0915880B1/en not_active Expired - Lifetime
- 1997-07-23 RO RO99-00078A patent/RO121272B1/ro unknown
- 1997-07-23 EA EA200301042A patent/EA006626B1/ru not_active IP Right Cessation
- 1997-07-23 AU AU38942/97A patent/AU747708B2/en not_active Expired
- 1997-07-23 PT PT97936222T patent/PT915880E/pt unknown
- 1997-07-23 HU HU0500549A patent/HU229024B1/hu unknown
- 1997-07-23 CZ CZ2005-613A patent/CZ2005613A3/cs unknown
- 1997-07-23 DE DE69738197T patent/DE69738197T2/de not_active Expired - Lifetime
- 1997-07-23 EP EP07015514A patent/EP1908764A1/en not_active Withdrawn
- 1997-07-23 WO PCT/US1997/013072 patent/WO1998003510A1/en active IP Right Grant
- 1997-07-23 KR KR1019997000568A patent/KR100548853B1/ko not_active IP Right Cessation
- 1997-07-23 HU HU0102187A patent/HU228962B1/hu unknown
- 1997-07-23 ES ES97936222T patent/ES2294800T3/es not_active Expired - Lifetime
- 1997-07-24 AR ARP970103368A patent/AR007994A1/es unknown
- 1997-07-25 TW TW092105694A patent/TWI238164B/zh not_active IP Right Cessation
- 1997-07-25 TW TW086110640A patent/TW542827B/zh not_active IP Right Cessation
-
1999
- 1999-01-20 LV LVP-99-13A patent/LV12292B/en unknown
-
2003
- 2003-07-02 HK HK03104703.7A patent/HK1052693A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20000068010A (ko) | 2000-11-25 |
HUP0102187A3 (en) | 2002-12-28 |
KR100548853B1 (ko) | 2006-02-02 |
AU747708B2 (en) | 2002-05-23 |
LV12292A (lv) | 1999-06-20 |
EP0915880A1 (en) | 1999-05-19 |
ES2294800T3 (es) | 2008-04-01 |
TWI238164B (en) | 2005-08-21 |
DE69738197T2 (de) | 2008-07-17 |
PT915880E (pt) | 2007-12-31 |
LV12292B (en) | 1999-11-20 |
AR007994A1 (es) | 1999-11-24 |
DK0915880T3 (da) | 2008-02-11 |
RO121272B1 (ro) | 2007-02-28 |
WO1998003510A1 (en) | 1998-01-29 |
TW200304916A (en) | 2003-10-16 |
HUP0102187A2 (hu) | 2001-11-28 |
AU3894297A (en) | 1998-02-10 |
HU228962B1 (en) | 2013-07-29 |
HU229024B1 (en) | 2013-07-29 |
HU0500549D0 (en) | 2005-08-29 |
EA006626B1 (ru) | 2006-02-24 |
HK1052693A1 (zh) | 2003-09-26 |
ATE375344T1 (de) | 2007-10-15 |
EP0915880B1 (en) | 2007-10-10 |
TW542827B (en) | 2003-07-21 |
EP1908764A1 (en) | 2008-04-09 |
CZ2005613A3 (cs) | 2017-01-25 |
DE69738197D1 (de) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200301042A1 (ru) | Азолопиримидины | |
EA199900853A1 (ru) | Замещенные производные бензопирана для лечения воспалительных процессов | |
TR199900239T2 (ru) | ||
DE69822665D1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
FR2380266A1 (fr) | Molybdates d'amines heterocycliques, procede d'obtention et application | |
ES2094733T3 (es) | Deteccion de enfermedades o disfunciones neurologicas. | |
EA200100451A1 (ru) | Замещенные аналоги бензопирана для лечения воспаления | |
EA199900758A1 (ru) | Малые молекулы, полезные при лечении воспалительных заболеваний | |
CY1105836T1 (el) | 12, 13-τροποποιημενα παραγωγα εποθιλονης | |
EA199900620A1 (ru) | Фталазиноны | |
EA199800733A1 (ru) | Антагонисты рецептора il-8 | |
EA200500249A1 (ru) | Применение соединений для лечения заболевания, опосредованного vcam-1 | |
EA199900326A1 (ru) | Промежуточные соединения и способ получения оланзапина | |
EA200000741A1 (ru) | Новые производные дигидроксигексановой кислоты | |
DE69127947T2 (de) | Monoklonale Antikörper gegen menschliches IgE | |
EA199901113A1 (ru) | Карбоксамиды в качестве агонистов 5-ht1f | |
GB0227655D0 (en) | Use | |
FR2423492A1 (fr) | Nouvelles indolo (2,3-a)-quinolizidines et leur methodes de preparation | |
ES2194102T3 (es) | Nuevas n-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas. | |
EA200200955A1 (ru) | Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона | |
FR2398731A1 (fr) | Nouveaux derives du maleinimide et du succinimide utiles comme herbicides | |
PT734380E (pt) | 4-benzoilisoxazois e sua utilizacao como herbicidas | |
ATE113591T1 (de) | 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva. | |
EA200000448A1 (ru) | Новые полиморфные формы ципамфиллина | |
EA200000069A1 (ru) | Способ получения 4-замещенных-1h-индол-3-глиоксамидов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change in name of a patent proprietor in a eurasian patent |
Designated state(s): AM AZ KG MD TJ TM |
|
MK4A | Patent expired |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |